Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-936557 · 1 trial · 1 indication
CDAI: Crohn's Disease Activity Index
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Induction | EXPERIMENTAL | Placebo |
| Cohort 2: Induction | EXPERIMENTAL | Anti-IP-10 Antibody |
| Cohort 3: Induction | EXPERIMENTAL | Anti-IP-10 Antibody |
| Cohort 1: Maintenance | EXPERIMENTAL | Placebo |
| Cohort 2: Maintenance | EXPERIMENTAL | Anti-IP-10 Antibody |
| Cohort 3: Maintenance | EXPERIMENTAL | Anti-IP-10 Antibody |
| Cohort 1: Open Label | EXPERIMENTAL | Anti-IP-10 Antibody |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks |
| BMS-936557 (Anti-IP-10 Antibody) | DRUG | Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks |
Inclusion Criteria: * Adults subjects with confirmed Crohn's Disease (CD) for at least 3 months * Moderate to severely active CD as defined by Crohn's Disease Activity Index (CDAI) 220 to 450 * In the past have had insufficient response and or intolerance to ≥ 1 of the conventional therapy (immunos...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
BMS-936557 is an investigational small molecule being studied for the treatment of moderate to severely active Crohn's Disease, a type of inflammatory bowel disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
BMS-936557 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Crohn's Disease.
BMS-936557 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied for the treatment of moderate to severely active Crohn's Disease.
BMS-936557 has one completed Phase 2 clinical trial registered under NCT01466374, titled 'Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease.' The trial enrolled 121 participants across multiple countries including the United States, Belgium, France, Hungary, Israel, Poland, Puerto Rico, and South Africa.
BMS-936557 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Crohn's Disease. The drug has completed one clinical trial, but it has not yet received regulatory approval for any use.